Just reported
Q3 2026 results
From Jazz Pharmaceuticals plc's results release of November 2, 2026; its quarterly report has since been filed.
Revenue
Actual
$1.24B
+10% y/y ↑
+2.9% q/q ↑
EPS, GAAP
Operating income, GAAP
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|
| Total Revenue | $1.2B | $1.1B | +10.38% |
| Profit | -$483.4M | $251.4M | -292.28% |
| Profit per share | -$7.48 | $4.08 | -283.33% |
| Free Cash Flow | $489.9M | $459.5M | +6.62% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingJazz Pharmaceuticals plc reported on November 2, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$215.98
Oct 30, 2026
Close after
$229.74
Nov 3, 2026
Move
+6.37%
1.68M shares traded, against a normal 800.47K
The quote and the company description come from Jazz Pharmaceuticals plc’s Item 2.02 8-K filed November 2, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
